Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Mantle Cell Lymphoma

Trial Name: A Research Study of An Intergroup Randomized Phase II Four Arm Study In Patients ? 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR).

Protocol ID: E1411

Eligibility:

Eligibility:

  • Age > 60 years
  • Females of childbearing potential must not be pregnant or breast-feeding due to risk of fetal harm by the chemotherapeutic agents prescribed in this protocol.
  • Women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception
  • Histologically confirmed untreated mantle cell lymphoma
  • Must meet required laboratory values
  • No evidence of prior malignancy except adequately treated, non-melanoma skin cancer, in situ cervical carcinoma or any surgically or radiation-cured malignancy continuously disease free for > 5 years so as not to interfere with interpretation of radiographic response
  • Patient must have no CNS involvement
  • HIV positive patients are not excluded, but to enroll must meet all study criteria

Patients must not have hypersensitivity to bortezomib, boron or mannitol

Enrollment: 332 people

Benefits:

Taking part in this study may or may not make your health better.  While doctors hope the drugs used in this study will be more useful against cancer compared to the usual treatment, there is no proof of this.  We do know that the information from this study will help doctors learn more about the way that combined chemotherapy drugs work together as a treatment for cancer.  This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jan 18, 2013

Updated: Jan 18, 2013

« Return to Trials